This Pharma Firm Passes the Test
April 29, 2015 at 08:00 AM EDT
Positive trial data for diabetes drug Januvia and strong first-quarter results keep Merck's stock undervalued and its wide moat intact.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.